Market closedNon-fractional
Citius Pharmaceuticals/CTXR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Citius Pharmaceuticals
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Ticker
CTXR
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Cranford, United States
Employees
22
Website
citiuspharma.com
CTXR Metrics
BasicAdvanced
$96M
Market cap
-
P/E ratio
-$0.24
EPS
1.54
Beta
-
Dividend rate
Price and volume
Market cap
$96M
Beta
1.54
Financial strength
Current ratio
5.169
Quick ratio
3.009
Long term debt to equity
0.181
Total debt to equity
0.469
Management effectiveness
Return on assets (TTM)
-25.08%
Return on equity (TTM)
-42.15%
Valuation
Price to book
1.06
Price to tangible book (TTM)
7.91
Price to free cash flow (TTM)
-2.754
Growth
Earnings per share change (TTM)
7.53%
3-year earnings per share growth
-11.78%
What the Analysts think about CTXR
Analyst Ratings
Majority rating from 2 analysts.
CTXR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.5M
-7.61%
Profit margin
0.00%
NaN%
CTXR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.06
-$0.07
-$0.06
-$0.05
-
Expected
-$0.06
-$0.02
$0.13
-$0.06
-$0.06
Surprise
9.09%
250.00%
-146.15%
-16.67%
-
CTXR News
AllArticlesVideos
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
PRNewsWire·1 month ago
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
PRNewsWire·2 months ago
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Citius Pharmaceuticals stock?
Citius Pharmaceuticals (CTXR) has a market cap of $96M as of July 06, 2024.
What is the P/E ratio for Citius Pharmaceuticals stock?
The price to earnings (P/E) ratio for Citius Pharmaceuticals (CTXR) stock is 0 as of July 06, 2024.
Does Citius Pharmaceuticals stock pay dividends?
No, Citius Pharmaceuticals (CTXR) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Citius Pharmaceuticals dividend payment date?
Citius Pharmaceuticals (CTXR) stock does not pay dividends to its shareholders.
What is the beta indicator for Citius Pharmaceuticals?
Citius Pharmaceuticals (CTXR) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Citius Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.